Search
Search
Joseph Allen, OD, FAAO, Dipl ABO
Show Description +
The first FDA-approved treatment for Demodex blepharitis has arrived, and Joseph J. Allen, OD, FAAO, Dipl ABO, reviews what you need to know to start using it in your clinic. He discusses the novel mechanism of action of lotilaner ophthalmic solution 0.25% (Xdemvy, formerly TP-03; Tarsus Pharmaceuticals), its side effects, dosing, clinical trial data, information for prescribing, and more.
Posted: 9/05/2023
Joseph Allen, OD, FAAO, Dipl ABO
The first FDA-approved treatment for Demodex blepharitis has arrived, and Joseph J. Allen, OD, FAAO, Dipl ABO, reviews what you need to know to start using it in your clinic. He discusses the novel mechanism of action of lotilaner ophthalmic solution 0.25% (Xdemvy, formerly TP-03; Tarsus Pharmaceuticals), its side effects, dosing, clinical trial data, information for prescribing, and more.
Posted: 9/05/2023
.mp4.00_05_41_04.Still001_1680887186.jpg?auto=compress,format&w=180)
.00_13_09_19.Still001_1676069079.jpg?auto=compress,format&w=180)
_1701789080.png?auto=compress,format&w=180)
Please log in to leave a comment.